Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd Share Price Today: Live Updates & Key Insights

Get insights on Caplin Point Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Caplin Point Laboratories Ltd Share Price Chart

Caplin Point Laboratories Ltd Fundamentals

Traded Volume: 59,702

Market Cap(Cr): 14,585

Avg Traded Price 1919.46

1 Year return -1.24%

Upper Circuit 1,934.7

Lower Circuit 1,905

P/E TTM 25.00

P/B Ratio 77.00

Traded Value(Cr) 1145.56

EPS TTM 77.459

Book value 77.459

Dividend 0.00%

Caplin Point Laboratories Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Caplin Point Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Caplin Point Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -0.91%

1M -4.57%

3M -9.53%

1Y -1.24%

YTD -23.56%

Caplin Point Laboratories Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Caplin Point Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 23799.00

Day Before Yesterday 40145.00

1W Avg 41559.00

1M Avg 55218.81

3M Avg 79535.05

Caplin Point Laboratories Ltd Technical Details

Caplin Point Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 1904

Support 2 1890

Support 3 1875

Pivot Point : 1920

Resistance 1 1934

Resistance 2 1949

Resistance 3 1964

Caplin Point Laboratories Ltd Corporate Actions

Caplin Point Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Caplin Point Laboratories Ltd’s capital allocation strategies.

All

Ex-Date 12-Sep-2025 Type D Description 3.00/share@150.00% Record Date 12-Sep-2025 Ratio 150.00

Ex-Date 30-May-2025 Type D Description 3.00/share@150.00% Record Date 30-May-2025 Ratio 150.00

Ex-Date 23-Sep-2024 Type D Description 2.50/share@125.00% Record Date 23-Sep-2024 Ratio 125.00

Ex-Date 31-May-2024 Type D Description 2.50/share@125.00% Record Date 31-May-2024 Ratio 125.00

Ex-Date 14-Sep-2023 Type D Description 2.50/share@125.00% Record Date 14-Sep-2023 Ratio 125.00

Ex-Date 09-Jun-2023 Type D Description 2.00/share@100.00% Record Date 09-Jun-2023 Ratio 100.00

Ex-Date 21-Sep-2022 Type D Description 2.00/share@100.00% Record Date 22-Sep-2022 Ratio 100.00

Ex-Date 23-May-2022 Type D Description 2.00/share@100.00% Record Date 24-May-2022 Ratio 100.00

Ex-Date 20-Sep-2021 Type D Description 1.50/share@75.00% Record Date 21-Sep-2021 Ratio 75.00

Ex-Date 18-May-2021 Type D Description 1.50/share@75.00% Record Date 19-May-2021 Ratio 75.00

Ex-Date 21-Sep-2020 Type D Description 0.40/share@20.00% Record Date - Ratio 20.00

Ex-Date 12-Mar-2020 Type D Description 2.10/share@105.00% Record Date 13-Mar-2020 Ratio 105.00

Ex-Date 04-Sep-2019 Type D Description 2.20/share@110.00% Record Date - Ratio 110.00

Ex-Date 18-Sep-2018 Type D Description 2.00/share@100.00% Record Date - Ratio 100.00

Ex-Date 07-Sep-2017 Type D Description 1.50/share@75.00% Record Date - Ratio 75.00

Ex-Date 19-Oct-2016 Type S Description share@1:5.00 Record Date 20-Oct-2016 Ratio 1:5.00

Ex-Date 01-Sep-2016 Type D Description 3.50/share@35.00% Record Date - Ratio 35.00

Ex-Date 15-Feb-2016 Type D Description 2.50/share@25.00% Record Date 16-Feb-2016 Ratio 25.00

Ex-Date 29-Oct-2015 Type D Description 5.00/share@50.00% Record Date - Ratio 50.00

Ex-Date 11-Dec-2014 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00

Ex-Date 19-Dec-2013 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 11-Dec-2012 Type D Description 2.00/share@20.00% Record Date 13-Dec-2012 Ratio 20.00

Ex-Date 12-Dec-2011 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 09-Dec-2010 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00

Dividends

Announcement Date 12-Sep-2025 Ex Dividend Date 12-Sep-2025 Dividend(%) 150

Announcement Date 30-May-2025 Ex Dividend Date 30-May-2025 Dividend(%) 150

Announcement Date 23-Sep-2024 Ex Dividend Date 23-Sep-2024 Dividend(%) 125

Announcement Date 31-May-2024 Ex Dividend Date 31-May-2024 Dividend(%) 125

Announcement Date 14-Sep-2023 Ex Dividend Date 14-Sep-2023 Dividend(%) 125

Announcement Date 09-Jun-2023 Ex Dividend Date 09-Jun-2023 Dividend(%) 100

Announcement Date 21-Sep-2022 Ex Dividend Date 21-Sep-2022 Dividend(%) 100

Announcement Date 23-May-2022 Ex Dividend Date 23-May-2022 Dividend(%) 100

Announcement Date 20-Sep-2021 Ex Dividend Date 20-Sep-2021 Dividend(%) 75

Announcement Date 18-May-2021 Ex Dividend Date 18-May-2021 Dividend(%) 75

Announcement Date 21-Sep-2020 Ex Dividend Date 21-Sep-2020 Dividend(%) 20

Announcement Date 12-Mar-2020 Ex Dividend Date 12-Mar-2020 Dividend(%) 105

Announcement Date 04-Sep-2019 Ex Dividend Date 04-Sep-2019 Dividend(%) 110

Announcement Date 18-Sep-2018 Ex Dividend Date 18-Sep-2018 Dividend(%) 100

Announcement Date 07-Sep-2017 Ex Dividend Date 07-Sep-2017 Dividend(%) 75

Announcement Date 01-Sep-2016 Ex Dividend Date 01-Sep-2016 Dividend(%) 35

Announcement Date 15-Feb-2016 Ex Dividend Date 15-Feb-2016 Dividend(%) 25

Announcement Date 29-Oct-2015 Ex Dividend Date 29-Oct-2015 Dividend(%) 50

Announcement Date 11-Dec-2014 Ex Dividend Date 11-Dec-2014 Dividend(%) 40

Announcement Date 19-Dec-2013 Ex Dividend Date 19-Dec-2013 Dividend(%) 25

Announcement Date 11-Dec-2012 Ex Dividend Date 11-Dec-2012 Dividend(%) 20

Announcement Date 12-Dec-2011 Ex Dividend Date 12-Dec-2011 Dividend(%) 15

Announcement Date 09-Dec-2010 Ex Dividend Date 09-Dec-2010 Dividend(%) 10

Bonus

No Bonus has been declared by CAPLIPOINT

Splits

Record Date 20-Oct-2016 Split Date 19-Oct-2016 Face Value (Before/After) 10.00/2.00

Others

Rights No Rights has been declared by CAPLIPOINT

Caplin Point Laboratories Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Caplin Point Laboratories Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Caplin Point Laboratories Ltd's relative performance and valuation against major competitors.

Stock Name Alembic Pharmaceuticals Ltd ₹901.00 (+0.17%) M. Cap (Cr) 177.10 1 Yr Return (%) -13.19% P/E (TTM) 27.92 PB Ratio 3.41

Stock Name Jubilant Pharmova Ltd ₹1057.80 (-2.06%) M. Cap (Cr) 168.51 1 Yr Return (%) -6.42% P/E (TTM) 35.27 PB Ratio 2.84

Stock Name Natco Pharma Ltd ₹864.80 (-0.52%) M. Cap (Cr) 154.89 1 Yr Return (%) -37.09% P/E (TTM) 10.07 PB Ratio 2.04

Stock Name Caplin Point Laboratories Ltd ₹1918.80 (-0.09%) M. Cap (Cr) 145.85 1 Yr Return (%) -1.24% P/E (TTM) 24.77 PB Ratio 5.74

Stock Name Acutaas Chemicals Ltd ₹1701.80 (-1.77%) M. Cap (Cr) 139.33 1 Yr Return (%) +62.23% P/E (TTM) 62.21 PB Ratio 11.59

Stock Name Granules India Ltd ₹544.20 (-1.20%) M. Cap (Cr) 132.06 1 Yr Return (%) -0.12% P/E (TTM) 25.75 PB Ratio 3.55

Stock Name Rubicon Research Ltd ₹677.90 (-2.62%) M. Cap (Cr) 111.68 1 Yr Return (%) NaN% P/E (TTM) PB Ratio 18.78

Caplin Point Laboratories Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Caplin Point Laboratories Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 195.87 Mar 2024 111.01 Mar 2023 157.10 Mar 2022 230.97 Mar 2021 294.65

PARTICULARS Investing Activities Mar 2025 -140.20 Mar 2024 -118.94 Mar 2023 -86.67 Mar 2022 -237.18 Mar 2021 16.28

PARTICULARS Financing Activities Mar 2025 -38.10 Mar 2024 -34.26 Mar 2023 -30.42 Mar 2022 -22.76 Mar 2021 -3.46

PARTICULARS Net Cash Flow Mar 2025 19.00 Mar 2024 -41.38 Mar 2023 41.01 Mar 2022 -29.06 Mar 2021 307.28

Caplin Point Laboratories Ltd Shareholding Pattern

This shows the ownership breakdown of Caplin Point Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 70.57%

Public 20.82%

Other Institutions 0.31%

FII 6.51%

Mutual Funds 1.79%

About Caplin Point Laboratories Ltd

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990. The Company is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections.Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil).The company came out with a public issue in Nov.'94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories, US, for specific products, with a 30% buyback arrangement. It also imports bio-technological products to market them in India.The company has established a trading branch in Nairobi, Kenya, to sell its products in East Africa. It has also established a warehouse in Miami, US, by entering into a marketing tie-up with Lockett Medical Corporation, US.During the year 2015, the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Company's share in LLP has increased to 99.90% in Argus Salud Pharma LLP.In October 2016, the Company had subdivided the shares from the face value of Rs 10/- to Rs 2/- and upon sub-division, the members were issued five equity shares of Rs 2/- each in lieu of one equity share of Rs 10/- each. After sub-division, the paid up capital of Rs15,11,00,000 was sub- divided into 7,55,50,000 equity shares of Rs 2/- each.As on 31 March 2018, the Company has three subsidiaries, viz Argus Salud Pharma LLP, Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia.During the year 2019, the Company transferred its regulated markets injectable business which, inter-alia includes US FDA approved injectable plant and Department of Science and Industrial Research (DSIR) recognised R& D Units CP4 and CP 5 to Caplin Steriles Limited, a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31, 2018.In FY2019, the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and F-Prime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares (CCPS), which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms.During FY 2019, the Company formed a Joint Venture, Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China, which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China, India, Europe and Latin America.In FY'21, Company acquired four channel partners in Latin America, strengthening control on marketing, distribution and supply chain. It launched an e-commerce website named `QueTenX', a part of the 10X healthcare portal, transforming credit sales into cash, enhancing an analysis of demand and supply patterns and replenishment stocks through technology tools. It deepened capabilities by stocking essential products at warehouses during the COVID-19 months. It commissioned a DGCI-approved CRO facility and captive API development kilo lab to facilitate backward integration. It received approvals for nine of 18 ANDAs filed (six for Caplin Steriles); five products launched; the next four to be launched in the near future. It embarked on a pipeline of 15 ANDAs to be filed within 24 months with an addressable market size of USD 1.95 billion. It completed ab scale batches for 17 products for US (by Caplin's API division) and trebled capacity of the manufacturing facility.The Company received four ANDA approvals since January 2021, increasing approved ANDAs to 15 (ten under Caplin's name and five through partners). It launched eight products in US; four products are ready for launch and three are likely to be launched before December 2021. It received large tender orders worth $18 million in two markets and has started R&D for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress as such. The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs. 140 Crore and will include 2 Vial lines, one Lyophilizer line, one Pre- filled syringe line and provision to add another Pre-mix bag line.During the year 2022-23, the Company had disposed its entire investment in Caplin Point Laboratories Colombia SAS to Caplin Point Far East Limited - Hong Kong, a wholly - owned subsidiary of the Company and effective from March 28, 2023, Caplin Point Laboratories Colombia SAS ceased to be a subsidiary but became a step-down subsidiary.In 2023, Caplin doubled its capacity to produce Softgel formulation at its Puducherry facility. The Company implemented the latest, S4 hana, version of SAP - enterprise resource planning system. It developed new line of products i.e. Oncology. It completed 4 complex products Exhibit Batches, which includes 3 Injectables and 1 Ophthalmic; launched co-labelled products in the US, for 4 approved products. It launched 23 new products in Central America which has contributed to $2.4m dollars in sale. The second line of production in Softgel dosage was completed in 2023. The Company acquired an API plant in Visakhapatnam, Andhra Pradesh during the year 2024. Oncology facility started production at SIDCO Kalkkalur, Chennai in March, 2025.

Chairman (Non-Executive)

C C Paarthipan

Registered office Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat, Chennai, Tamil Nadu, 600096

FAX :91-44-24968000/71148000/28156653

Background

Incorporation Year 1990

Face Value ₹2.00

Market Lot 1

Caplin Point Laboratories Ltd Latest News

VIEW MORE NEWS

FAQs on Caplin Point Laboratories Ltd